Abstract
Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Volume: 8 Issue: 4
Author(s): Fabrizio Montecucco and Francois Mach
Affiliation:
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Abstract: Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Export Options
About this article
Cite this article as:
Montecucco Fabrizio and Mach Francois, Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187153008786848268
DOI https://dx.doi.org/10.2174/187153008786848268 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intramolecular Processes and Their Applications in Prodrugs Approaches- Experimental and Computational Studies
Current Organic Chemistry Single Emulsion-Solvent Evaporation Technique and Modifications for the Preparation of Pharmaceutical Polymeric Nanoparticles
Recent Patents on Drug Delivery & Formulation The Vicious Circle of Leptin and Obesity
Current Nutrition & Food Science Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease
Current Cardiology Reviews G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Quantification of Low-Density and High-Density Lipoproteins in Human Serum by Material Enhanced Infrared Spectroscopy (MEIRS)
Current Medicinal Chemistry Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Potential Therapeutic Effects of Physical Exercise for Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Selections:
Recent Patents on Regenerative Medicine Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews